Verdict No. 3052 · Search date 2026-09-08 · Methodology v1.0
500-mg dried ginger-powder capsules,
does it really help with Reduction of LDL cholesterol in adults?
30-Second Summary
C
Evidence Grade C · 50 · Safety caution
This verdict addresses LDL cholesterol only; triglycerides, HDL, and total cholesterol are separate.
Caution. Do not stop lipid-lowering therapy. Review gastrointestinal effects and possible interactions, including anticoagulants and antiplatelets.
What the
research showsGrade C with 50 points. In the verified 2-g/day ten-week trial, final LDL-C was 100 versus 107 mg/dL (P=.57), and LDL was a registered secondary endpoint. Recent syntheses respectively crossed zero and were only borderline positive, so this secondary null result was not relabeled as a failed primary endpoint.
research showsGrade C with 50 points. In the verified 2-g/day ten-week trial, final LDL-C was 100 versus 107 mg/dL (P=.57), and LDL was a registered secondary endpoint. Recent syntheses respectively crossed zero and were only borderline positive, so this secondary null result was not relabeled as a failed primary endpoint.
What the
ads claimThe evidence does not support statin replacement, cardiovascular prevention, or marketing triglyceride improvement as an LDL effect.
ads claimThe evidence does not support statin replacement, cardiovascular prevention, or marketing triglyceride improvement as an LDL effect.
Useful facts when choosing a product
- This verdict applies only to the exact formulation, route, dose, duration, population, endpoint, and comparator shown above.
- Ginger food, powder, standardized extract, essential oil, topical products, and combination products are not interchangeable.
- Caution. Do not stop lipid-lowering therapy. Review gastrointestinal effects and possible interactions, including anticoagulants and antiplatelets.
Chamgap Semantic Classification Code
Permanent code issued
S.ginger.oral.ldl-cholesterol.reduce.placeboSupplements and nutraceuticals > Ginger > Oral > LDL cholesterol > Reduction claim > Placebo or control care
The latest pooled null result remains retrievable; triglycerides and HDL are separate. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Ginger |
| Source or part used | Rhizome of Zingiber officinale Roscoe |
| Formulation or processing | 500-mg dried ginger-powder capsules; gingerol/shogaol assay unverified |
| Route | Oral |
| Dose | 1 g twice daily, 2 g/day total |
| Duration | Ten weeks |
| Population | Adults with type 2 diabetes on oral medication; not a verified statin add-on population |
| Effect or condition | LDL-cholesterol reduction |
| Primary endpoint | Between-group LDL-C difference at ten weeks |
| Comparator | Wheat-flour placebo plus usual care; lipid medication inadequately controlled |
| Duplicate-detection key | ginger|500mg-dried-powder-capsules|oral|adults-t2d-on-oral-medication|ldl-reduction|10-weeks |
Gap Measurement · Verdict 3052 · C 50
What the research actually shows
Meta-analyses from 2018, 2022, and 2023 were compared, retaining only direct LDL estimates.
Why this is classified as C (50)
Academic support is a strength, but LDL was secondary, pooled estimates conflict with high heterogeneity, exact change and precision are unavailable, and the trial was small and short; the result is C with 50 points.
Counterpoint. A 26-trial 2022 analysis estimated a 5.14-mg/dL reduction, but it did not agree with the later synthesis.
Rejudgment record. Independent Codex cross-check — One formulation, one route, one population, one claim, one principal endpoint and comparator
Scoring profile behind this grade
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | EX | The clinical size of the effect could not be judged |
| Precision | CX | No pooled confidence interval could be confirmed |
The scoring table and the verdict agree (C).
Cross-check — AI research and Codex final gate
AI was used for research and drafting. Blind grading, adversarial audit, and the methodology boundary rules were then reapplied before Codex performed the final evidence, grade, copy, and build checks. If a grade cannot be narrowed, both evidence positions and their reasons are published.
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| The Effects of Ginger on Fasting Blood Sugar, Hemoglobin A1c, and Lipid Profiles in Patients with Type 2 Diabetes | The cited design, allocation, masking, endpoint hierarchy, and analysis limitations were independently checked. | 22 | Funding, product support, employee authorship, and declared conflicts were assessed separately. | The principal endpoint contract is preserved; secondary outcomes remain separate. | Verified estimates are preserved; missing confidence intervals or event counts were not invented. | Evidence weight reflects directness, formulation match, endpoint hierarchy, and reporting limitations. |
| Meta-analysis of the effects of ginger supplementation on glycemic control, blood pressure and lipid profile in patients with type 2 diabetes | The cited design, allocation, masking, endpoint hierarchy, and analysis limitations were independently checked. | 13 | Funding, product support, employee authorship, and declared conflicts were assessed separately. | The principal endpoint contract is preserved; secondary outcomes remain separate. | Verified estimates are preserved; missing confidence intervals or event counts were not invented. | Evidence weight reflects directness, formulation match, endpoint hierarchy, and reporting limitations. |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-09-08).
Makhdoomi Arzati M et al. Int J Endocrinol Metab. 2017. PMID: 29344037. PMCID: PMC5750786. DOI: 10.5812/ijem.57927. NCT02666807.
checkedChen X et al. Syst Rev. 2026. PMID: 42337792. PMCID: PMC13495174. DOI: 10.1186/s13643-026-03251-5.
checkedResearch and draft: AI used · Cross-check: blind grading and adversarial audit
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Final verification and publication gate: Codex · Verification cutoff: 2026-09-08 · Corrections: none
Cite this verdict
[Chamgap] Ginger Powder for LDL Cholesterol—The Ten-Week Trial Was Unconfirmed and Pooled Results Conflict — Evidence Grade C·50. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/oral-ginger-adults-ldl-cholesterol/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.